What is CalciMedica's market cap?

CalciMedica (CALC) has a market capitalization of $15.0M and trades on NASDAQ.

Who are CalciMedica's competitors?

CalciMedica's key competitors include Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, and others. These companies compete in similar markets and product categories.

Who does CalciMedica partner with?

CalciMedica's notable partners include St. Jude Children's Research Hospital, Charité – University Medicine Berlin, New York University Grossman School of Medicine, and others.

Where is CalciMedica headquartered?

CalciMedica is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2020.

CalciMedica

CALC

CalciMedica is a clinical-stage biopharmaceutical company developing a new class of small-molecule therapeutics that target calcium release-activated calcium (CRAC) channels.

Market cap

$15.01M-33.7%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$0.30Miss by $0.02

Read the full report

Next report

Aug 11, 2026 (in a month)

EPS estimate-$0.33

Competitors

By market cap

Arrowhead Research$11.8B+409%

Ionis Pharmaceuticals$10.6B+59.7%

TFX

Teleflex$5.9B+15.1%

IAR

Integra LifeSciences$1.4B+44.4%

CorMedix$680.2M-20.0%

Cytosorbents$23.4M-63.7%

Citius Pharmaceuticals$15.4M-34.5%

CalciMedica$15.0M-33.3%

By revenue growth

CorMedix+385%

Ionis Pharmaceuticals+47.5%

TFX

Teleflex+25.0%

Arrowhead Research+14.1%

IAR

Integra LifeSciences+1.2%

By net margin

CorMedix45.25%+58.3pp

IAR

Integra LifeSciences-30.15%-27.0pp

Ionis Pharmaceuticals-30.9%+33.0pp

TFX

Teleflex-47.43%-56.2pp

Arrowhead Research-48.38%-22.0pp

Profile

CalciMedica is a clinical-stage biopharmaceutical company developing a new class of small-molecule therapeutics that target calcium release-activated calcium (CRAC) channels. The company's platform addresses serious inflammatory and immunologic illnesses by modulating inflammatory signaling and protecting tissue cells from calcium-mediated injury. Its lead development programs focus on acute critical care settings where there are currently no approved disease-modifying therapies.

Competitive position

A pioneer in CRAC channel inhibition with a first-in-class clinical candidate targeting acute pancreatitis and other critical care indications.

GeographiesUnited States, European Union

Customer segmentsAcute care providers, Specialty healthcare providers

Business modelR&D-stage biotechnology, Drug development

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Raw material suppliers

CustomersHospitals, Specialty pharmacies, Pharmaceutical distributors

CountryUnited States of America

Listed2020

Employees13.0

CEOA. Rachel Leheny

SectorHealthcare

IndustryBiotechnology

Websitegraybug.vision

FilingsSEC EDGAR

Questions, answered.

What is CalciMedica's market cap?: CalciMedica (CALC) has a market capitalization of $15.0M and trades on NASDAQ.
Who are CalciMedica's competitors?: CalciMedica's key competitors include Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, and others. These companies compete in similar markets and product categories.
Who does CalciMedica partner with?: CalciMedica's notable partners include St. Jude Children's Research Hospital, Charité – University Medicine Berlin, New York University Grossman School of Medicine, and others.
Where is CalciMedica headquartered?: CalciMedica is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2020.